Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure Based Drug Design.
Hobson, A.D., Judge, R.A., Aguirre, A.L., Brown, B.S., Cui, Y., Ding, P., Dominguez, E., DiGiammarino, E., Egan, D.A., Freiberg, G.M., Gopalakrishnan, S.M., Harris, C.M., Honore, M.P., Kage, K.L., Kapecki, N.J., Ling, C., Ma, J., Mack, H., Mamo, M., Maurus, S., McRae, B., Moore, N.S., Mueller, B.K., Mueller, R., Namovic, M.T., Patel, K., Pratt, S.D., Putman, C.B., Queeney, K.L., Sarris, K.K., Schaffter, L.M., Stoll, V.S., Vasudevan, A., Wang, L., Wang, L., Wirthl, W., Yach, K.(2018) J Med Chem 61: 11074-11100
- PubMed: 30384606 
- DOI: https://doi.org/10.1021/acs.jmedchem.8b01098
- Primary Citation of Related Structures:  
6E99, 6E9L, 6E9W, 6ED6 - PubMed Abstract: 
A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH 2 , 2-F, 3-F) of the pyridine hinge binding motif or replacement with pyrimidine afforded compounds with a clean CYP inhibition profile ...